Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The company said the FDA’s written response to its Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The HARMONIC trial is a randomized, double-blind, placebo-controlled study assessing LP-300 plus standard chemotherapy versus chemotherapy alone. The FDA’s support for the amendments underscores the potential of LP-300 to address an unmet medical need in never-smokers, who represent a distinct subset of lung cancer patients with unique molecular characteristics. This population often exhibits EGFR mutations and has limited treatment options after progression on targeted therapies.
Lantern Pharma is a clinical-stage precision oncology company leveraging artificial intelligence and machine learning through its proprietary RADR platform to accelerate drug development. The company’s pipeline includes LP-184, LP-284, and LP-300. LP-300 is being evaluated in the HARMONIC trial in never-smoker patients with relapsed advanced lung adenocarcinoma following tyrosine kinase inhibitor (TKI) treatment. The company also operates withZeta.ai, a multi-agentic AI co-scientist platform now commercially available as a subscription-based research platform, representing a new revenue stream.
The FDA’s feedback is a significant milestone for Lantern Pharma, as it provides a more defined regulatory pathway for LP-300. The company plans to implement the protocol amendments, which include a refined focus on patients with the EGFR exon 21 L858R mutation. This mutation is common in never-smokers and has been associated with differential responses to certain therapies. The decision highlights the importance of precision medicine in oncology, where treatments are tailored to specific genetic profiles.
Investors and stakeholders can find more information about Lantern Pharma and its programs on the company’s newsroom at https://ibn.fm/LTRN. The full press release detailing the FDA’s response is available at https://ibn.fm/Rxklm.
